Triptorelin pamoate 11.25mg SR - 3 monthly Injection (Decapeptyl®)
Triptorelin pamoate 22.5mg SR - 6 monthly injection (Decapeptyl®)
Decapeptyl SR 22.5mg is considered first line LHRH analogue for new patients [1st dose should be a monthly prep to ensure tolerance]. Also consider a switch to 6 monthly preparation for anyone high risk for COVID-19 and currently receiving a 1 month or 3 monthly LHRH in line with guidance below.
For locally advanced, non-metastatic prostate cancer, as an alternative to surgical castration, or metastatic prostate cancer within the product licence.
RED - Hospital only – to be prescribed by a specialist and supplied from secondary care ONLY throughout treatment.
Amber medicines are considered suitable for GP prescribing following specialist initiation or recommendation.
Shared Care - these medicines require specialist initiation and stabilisation. Ongoing division of responsibility for drug and disease monitoring between specialist and GP by a Shared Care Guideline (SCG). If no SCG in place status reverts to red.
These medicines are appropriate for initiation in both primary and secondary care. Prescribing is appropriate within licensed or local recommendations.
Suitable for patient to be directed to buy themselves
Not currently used. We intend to include this TLS in future to highlight where a decision to use this medicine is under review.
(In use from Oct 2020) Used where a decision has been made by the BSW APC not to routinely commission this preparation for its licensed indications. Do not prescribe.
Not currently used. We intend to include this TLS in future to highlight where this medicine and indication is ONLY available through a Specialist Centre according to a NICE Highly Specialised Technology or NHSE Specialised Commission Circular / Policy.